ConvaTec Group PLC
LSE:CTEC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
213.4
293.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CTEC stock under the Base Case scenario is 278.46 GBX. Compared to the current market price of 235.8 GBX, ConvaTec Group PLC is Undervalued by 15%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
ConvaTec Group PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CTEC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
ConvaTec Group PLC
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
ConvaTec Group PLC is a global medical technology company that specializes in the development and marketing of advanced products for wound care, ostomy care, continence care, and critical care. Founded in 1978 and headquartered in the UK, ConvaTec has established itself as a leader in the healthcare space, relentlessly focusing on innovative solutions that enhance patient outcomes and streamline healthcare delivery. With a diverse portfolio of trusted brands such as AQUACEL® and Versiva®, the company provides essential products that cater to the needs of patients with chronic, acute, and complex wounds as well as those requiring ostomy care. The company's growth trajectory has been bolstered...
ConvaTec Group PLC is a global medical technology company that specializes in the development and marketing of advanced products for wound care, ostomy care, continence care, and critical care. Founded in 1978 and headquartered in the UK, ConvaTec has established itself as a leader in the healthcare space, relentlessly focusing on innovative solutions that enhance patient outcomes and streamline healthcare delivery. With a diverse portfolio of trusted brands such as AQUACEL® and Versiva®, the company provides essential products that cater to the needs of patients with chronic, acute, and complex wounds as well as those requiring ostomy care. The company's growth trajectory has been bolstered by strategic investments in research and development, positioning it as a pioneer in integrating cutting-edge technologies into its offerings.
As an investor, ConvaTec presents a compelling opportunity driven by increasing demand in the healthcare sector, notably due to an aging population, rising prevalence of chronic conditions, and heightened awareness of infection control. The company has demonstrated resilience and adaptability in navigating market fluctuations, evidenced by its strong revenue growth and operational improvements. With a robust pipeline of innovative products and a commitment to sustainability, ConvaTec is well-positioned to capitalize on emerging trends in healthcare. As healthcare evolves, its focus on delivering high-quality solutions not only enhances patient experiences but also promises to yield solid returns for investors looking to support the future of medical innovation.
ConvaTec Group PLC is a global medical technology company that specializes in providing innovative products and services in the healthcare sector. The core business segments of ConvaTec include:
-
Ostomy Care: This segment offers products designed for individuals who have undergone ostomy surgeries, which involve the creation of an artificial opening for waste removal. ConvaTec provides a range of ostomy pouches, skin barriers, and accessories that help improve the quality of life for ostomy patients.
-
Wound Care: ConvaTec's wound care segment focuses on advanced wound management and healing. This includes hydrocolloid wound dressings, foam products, alginates, and other advanced products that facilitate wound healing while minimizing discomfort and preventing infection.
-
Continence and Critical Care: This segment includes products for managing incontinence and bladder care, as well as critical care solutions for patients who require catheterization or have urinary problems. ConvaTec provides catheters and related products that aid in the management of urinary health.
-
Infusion Care: ConvaTec also offers products related to drug delivery, such as infusion devices and accessories. This segment is particularly important for patients requiring continuous medication or fluid therapy, covering a range of therapeutic areas.
These segments collectively enable ConvaTec to address a variety of healthcare needs, focusing on enhancing patient outcomes and improving the overall quality of care. Their commitment to innovation and quality has positioned them as a trusted partner in healthcare.
ConvaTec Group PLC, a global medical technology company specializing in advanced wound care, ostomy care, continence, and critical care, holds several unique competitive advantages over its rivals. Here are some key points:
-
Innovative Product Portfolio: ConvaTec is known for its advanced and innovative product offerings, particularly in wound care and ostomy products. The company invests significantly in research and development, allowing it to maintain a leading position in product efficacy and technological advancement.
-
Established Brand Recognition: With a strong brand reputation and long-standing presence in the market, ConvaTec has built trust with healthcare professionals and patients. This recognition can foster loyalty and preference among consumers.
-
Comprehensive Solutions: ConvaTec offers a broad range of integrated solutions across multiple therapeutic areas. This ability to provide comprehensive care solutions helps healthcare professionals to address multiple patient needs with one vendor, simplifying procurement and improving patient outcomes.
-
Focus on Patient-Centric Solutions: The company emphasizes patient-centered care by developing products that enhance patient quality of life and comfort. This focus can set ConvaTec apart in a marketplace that increasingly values patient experience.
-
Global Reach and Supply Chain Efficiency: ConvaTec operates in multiple regions worldwide, allowing it to leverage economies of scale and an efficient supply chain. This global footprint helps in efficiently serving a diverse customer base.
-
Strong Regulatory Compliance: ConvaTec has a robust regulatory framework in place to ensure compliance with healthcare regulations, which is critical for medical technology companies. This aspect can create barriers for competitors who may struggle with regulatory hurdles.
-
Strategic Partnerships: The company often engages in strategic partnerships and collaborations that enhance its development capabilities and market access. These alliances can lead to shared innovations and expanded market reach.
-
Patient and Healthcare Provider Support Programs: ConvaTec invests in education and support for both healthcare providers and patients. These programs can create a more informed user base and enhance product adoption.
-
Sustainability Initiatives: Increasingly, consumers and healthcare providers are looking for companies committed to sustainability. ConvaTec's efforts toward sustainable practices and products can appeal to this growing segment of the market.
-
Data-Driven Insights: The integration of data analytics and digital health solutions in their product offerings can provide valuable insights for healthcare providers, improving patient management and product effectiveness.
These competitive advantages enable ConvaTec to maintain a strong position in the medical technology sector, helping the company to differentiate itself from competitors while responding effectively to the needs of healthcare professionals and patients.
ConvaTec Group PLC, a company specializing in advanced medical technology products, faces several risks and challenges in the near future. Here are some key factors to consider:
-
Regulatory Challenges: The medical device industry is heavily regulated. Changes in regulations or delays in obtaining necessary approvals for new products could impact the company's ability to launch and market new innovations.
-
Competition: The healthcare sector is competitive, with both established players and new entrants. ConvaTec must continually innovate and improve its offerings to maintain or enhance its market share against competitors.
-
Supply Chain Disruptions: Ongoing global supply chain issues, exacerbated by factors such as geopolitical tensions or natural disasters, could affect the availability and cost of raw materials, impacting production schedules and profit margins.
-
Technological Advancements: Rapid advancements in medical technology may require continuous investment in research and development (R&D). If the company fails to keep pace, it may risk losing relevance in the market.
-
Market Dynamics: Fluctuations in demand due to economic conditions, changes in healthcare policies, or shifting patient demographics could affect the company’s sales and growth prospects.
-
Pricing Pressure: The increase in cost containment measures by healthcare providers and payers may lead to pricing pressure, affecting margins and profitability.
-
Cybersecurity Threats: As a modern medical technology firm, ConvaTec is susceptible to cyber threats that could compromise sensitive data and disrupt operations.
-
Reputation Management: Any negative publicity related to product safety or ethical practices could damage the company’s reputation, leading to decreased sales and litigation risks.
-
Economic Conditions: Economic downturns can influence healthcare spending. If healthcare budgets are reduced, this might impact the demand for ConvaTec's products, particularly in price-sensitive markets.
-
M&A Integration Risks: If ConvaTec pursues acquisitions to fuel growth, integration risks could arise, potentially diluting value and operational efficiency if not managed effectively.
-
Healthcare Trends: Shifts towards value-based care or emphasis on certain treatment methods over others might impact the company's product portfolio and growth strategies.
Understanding these risks and challenges is crucial for strategic planning and ensuring the long-term sustainability and growth of ConvaTec Group PLC.
Revenue & Expenses Breakdown
ConvaTec Group PLC
Balance Sheet Decomposition
ConvaTec Group PLC
Current Assets | 863.9m |
Cash & Short-Term Investments | 96.9m |
Receivables | 363.2m |
Other Current Assets | 403.8m |
Non-Current Assets | 2.8B |
Long-Term Investments | 19.8m |
PP&E | 544.8m |
Intangibles | 2.2B |
Other Non-Current Assets | 37.5m |
Current Liabilities | 381.6m |
Accounts Payable | 319.1m |
Other Current Liabilities | 62.5m |
Non-Current Liabilities | 1.6B |
Long-Term Debt | 1.4B |
Other Non-Current Liabilities | 196.8m |
Earnings Waterfall
ConvaTec Group PLC
Revenue
|
2.2B
USD
|
Cost of Revenue
|
-969m
USD
|
Gross Profit
|
1.2B
USD
|
Operating Expenses
|
-938.9m
USD
|
Operating Income
|
292.4m
USD
|
Other Expenses
|
-139.2m
USD
|
Net Income
|
153.2m
USD
|
Free Cash Flow Analysis
ConvaTec Group PLC
USD | |
Free Cash Flow | USD |
CTEC Profitability Score
Profitability Due Diligence
ConvaTec Group PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
ConvaTec Group PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
CTEC Solvency Score
Solvency Due Diligence
ConvaTec Group PLC's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
ConvaTec Group PLC's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTEC Price Targets Summary
ConvaTec Group PLC
According to Wall Street analysts, the average 1-year price target for CTEC is 302.76 GBX with a low forecast of 217.15 GBX and a high forecast of 362.25 GBX.
Dividends
Current shareholder yield for CTEC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
ConvaTec Group Plc operates as holding company, which engages in medical business. The company is headquartered in Reading, Berkshire and currently employs 10,025 full-time employees. The company went IPO on 2016-10-26. The firm focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. The company provides InnovaMatrixAC and InnovaBurn. The company markets and sell its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Its Advanced Wound Care (AWC) is an Advanced dressing for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Its Ostomy Care provides devices, accessories and services for people with a stoma (a surgically created opening where bodily waste is discharged), commonly resulting from causes such as colorectal cancer, inflammatory bowel disease and bladder cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one CTEC stock under the Base Case scenario is 278.46 GBX.
Compared to the current market price of 235.8 GBX, ConvaTec Group PLC is Undervalued by 15%.